Atomo Diagnostics (AT1) investor relations material

Executive summary

• Achieved significant improvement in gross margin to 51% from 39% year-over-year, driven by a shift away from lower-margin Global Health HIV business and cost reduction strategies.

• Revenue for FY2025 was $3.79 million, broadly in line with the prior year but down 7% from FY24, with improved profitability metrics and reduced EBITDA loss by 23% to $3.37 million.

• Raised just under $3 million in new capital, mainly from existing shareholders, and ended the year with $3.22 million in cash and no debt.

• Expanded commercial activities with major HIV self-test orders, a $2.44 million government grant for Active Syphilis test development, and new OEM agreements.

• Board refresh with new directors, resignations, and reduced annual board costs.

Financial highlights

• FY2025 revenue was $3.79 million, down 7% year-over-year, with gross margin improving to 51% from 39%.

• Gross profit rose 19% to $1.92 million, and underlying EBITDA loss reduced by 23% to $3.37 million.

• Operating expenses decreased by $650,000, reflecting ongoing cost-saving initiatives.

• Cash on hand at June 30 was $3.22 million, with an additional $1.32 million raised post year-end; no debt.

• Net cash outflow was within expectations, with $8.7 million in receipts and $9.1 million in payments.

Outlook and guidance

• Focus remains on margin expansion, cost efficiency, and operational leverage, with no significant CapEx required for future revenue growth.

• Anticipated Pascal revenues of up to US$6.9 million over three years, with further ramp-up expected.

• Commercial path to market for Active Syphilis test in Australia and Europe targeted for early CY 2027, seeking a U.S. partner.

• Expects further growth in HIV and syphilis test sales, especially in Australia, Europe, and new markets.